Entering text into the input field will update the search result below

Sanofi autoimmune skin candidate rilzabrutinib fails in phase 3

Sep. 10, 2021 8:34 AM ETSanofi (SNY) StockBy: Jonathan Block, SA News Editor

A case of pemphigus foliaceus in a male.
TARNXING Saetern/iStock via Getty Images

  • Rilzabrutinib, a candidate from Sanofi (NASDAQ:SNY) to treat emphigus, a rare autoimmune skin condition, missed primary and secondary endpoints in a phase 3 trial.
  • The primary endpoint was complete remission from weeks 29 to 37

Recommended For You

More Trending News

About SNY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SNY--
Sanofi